Publications in collaboration with researchers from Universidad de Salamanca (70)

2023

  1. Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study

    Blood Cancer Journal

  2. Characterization of the first HLA-DQA1 allele with Aspartic Acid in the transmembrane domain, HLA-DQA1*05:71

    HLA, Vol. 102, Núm. 3, pp. 381-383

  3. Detection and characterization of the novel HLA-DPA1*02:66:02N allele, with a premature stop codon in exon 2

    Human Immunology, Vol. 84, Núm. 4, pp. 296-300

  4. Identification of the novel HLA-DQA1*01:04:07 allele with a synonymous substitution and an intronic insertion

    HLA, Vol. 101, Núm. 5, pp. 559-561

  5. Identification of two novel HLA-DQB1*03:01:01 intronic variants: HLA-DQB1*03:01:01:47 and -DQB1*03:01:01:48

    HLA, Vol. 101, Núm. 5, pp. 562-564

  6. Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper

    Revista Espanola de Quimioterapia, Vol. 36, Núm. 1, pp. 1-25

  7. The novel HLA-DQB1*03:02:01:14 allele was possibly generated by a recombination event

    HLA, Vol. 102, Núm. 2, pp. 258-260

  8. Transitions in intronic regions result in two novel HLA-DQB1 alleles: –DQB1*05:02:01:13 and -DQB1*05:02:01:14

    HLA, Vol. 102, Núm. 2, pp. 260-262

2022

  1. Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 11, pp. 1196-1205

  2. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

    Science Advances, Vol. 8, Núm. 3

  3. RNA sequencing identifies novel regulated IRE1-dependent decay targets that affect multiple myeloma survival and proliferation

    Experimental Hematology and Oncology, Vol. 11, Núm. 1

2021

  1. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

2020

  1. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

    Blood, Vol. 135, Núm. 26, pp. 2375-2387

  2. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792

  3. Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma

    Blood Advances, Vol. 4, Núm. 23, pp. 6023-6033

  4. Zebularine-induced myeloma cell death is accompanied by decreased c-Myc expression

    Cellular Oncology, Vol. 43, Núm. 4, pp. 743-750

2018

  1. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

    Blood cancer journal, Vol. 8, Núm. 12, pp. 117

2017

  1. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma

    Journal of Molecular Diagnostics, Vol. 19, Núm. 1, pp. 99-106

  2. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

    Leukemia, Vol. 31, Núm. 10, pp. 2094-2103

2016

  1. Design and application of a 23-gene panel by next-generation sequencing for inherited coagulation bleeding disorders

    Haemophilia, Vol. 22, Núm. 4, pp. 590-597